跳转至内容
Merck
所有图片(1)

文件

341220

Sigma-Aldrich

Exo1

A cell-permeable methylanthranilate analog that reversibly inhibits vesicular traffic from ER to Golgi in mammalian cells by inducing tubulation and collapsing of the Golgi membrane.

别名:

Exo1, 2-(4-Fluorobenzoylamino)methylbenzoate, 2-(4-Fluorobenzoylamino)benzoic Acid Methyl Ester, ER Export Inhibitor I

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H12FNO3
CAS号:
分子量:
273.26
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥95% (HPLC)

形狀

solid

製造商/商標名

Calbiochem®

儲存條件

OK to freeze
protect from light

顏色

white

溶解度

DMF: 25 mg/mL
DMSO: 25 mg/mL
ethanol: 5 mg/mL
methanol: 5 mg/mL

運輸包裝

ambient

儲存溫度

2-8°C

InChI

1S/C15H12FNO3/c1-20-15(19)12-4-2-3-5-13(12)17-14(18)10-6-8-11(16)9-7-10/h2-9H,1H3,(H,17,18)

InChI 密鑰

KIAPWMKFHIKQOZ-UHFFFAOYSA-N

一般說明

A cell-permeable methylanthranilate analog that reversibly blocks vesicular traffic from the ER to the Golgi in mammalian cells (IC50 = 20 µM in BSC1 cells) by inducing tubulation and collapsing of the Golgi membrane and re-directing the traffic back to the ER. Acts as a potent and selective modifier of Golgi ARF1 GTPase activity. Unlike another membrane traffic inhibitor, Brefeldin A (BFA) (Cat. No. 203729), the effects appear to be limited to the Golgi, as no effects are detected on endocytic organelles, such as endosomes and trans-Golgi network (TGN). The inhibitory mechanism and target(s) appear to be different from those of BFA, thus making it a valuable alternative that complements BFA in membrane trafficking studies.
A cell-permeable methylanthranilate analog that reversibly inhibits vesicular traffic from ER to Golgi in mammalian cells (IC50 = 20 µM in BSC1 cells) by inducing tubulation and collapsing of the Golgi membrane and redirecting the traffic back to ER. Acts as a potent and selective modifier of Golgi ARF1 GTPase activity. Unlike another membrane traffic inhibitor Brefeldin A (BFA; Cat. No. 203729), its effect seems to be limited to Golgi, as no effect can be detected on endocytic organelles, such as endosomes and TGN (trans-Golgi network). Its inhibitory mechanism and target(s) appear to be quite different from those of BFA and thus serves as a valuable alternative that complements BFA in membrane traffic studies.

生化/生理作用

Cell permeable: yes
Primary Target
Golgi ARF1 GTPase
Product does not compete with ATP.
Reversible: yes
Target IC50: 20 µM inhibiting vesicular traffic from ER to Golgi in BSC1 cells

包裝

Packaged under inert gas

警告

Toxicity: Harmful (C)

重構

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

其他說明

Feng. Y., et al. 2003. Proc. Natl. Acad. Sci. USA100, 6469.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Chi-Ling Chiang et al.
Nature communications, 14(1), 6692-6692 (2023-10-24)
Pancreatic ductal adenocarcinoma (PDAC) tumours carry multiple gene mutations and respond poorly to treatments. There is currently an unmet need for drug carriers that can deliver multiple gene cargoes to target high solid tumour burden like PDAC. Here, we report

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门